ProBioGen Signs Second Contract Development Agreement with Tizona Therapeutics for Immuno-Oncology Antibody Project Read more
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials Read more
Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine Read more
Sobi Receives Approval from Health Canada for Once-Daily Dosing of Orfadin (nitisinone) for the Treatment of HT-1 Read more